{{Rsnum
|rsid=28399454
|Gene=CYP2A6
|Chromosome=19
|position=40845362
|Orientation=plus
|GMAF=0.02479
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CYP2A6
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 0.9 | 99.1
| HCB | 0.0 | 0.0 | 0.0
| JPT | 0.0 | 0.0 | 0.0
| YRI | 0.0 | 23.3 | 76.7
| ASW | 0.0 | 19.3 | 80.7
| CHB | 0.0 | 0.0 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 11.2 | 88.8
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs28399454
|Name_s=CYP2A6:47441C>T
|Gene_s=CYP2A6
|Feature=Exon/NonSyn
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/cyp2a6/variant.jsp
|Annotation=This variant decreases enzyme activity and affects metabolism of coumarin and nicotine; part of the CYP2A6*17 haplotype.
|Drugs=coumarin; nicotine
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145200
}}

{{PMID|19371316|OA=1
}} CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.

{{GET Evidence
|gene=CYP2A6
|aa_change=Val365Met
|aa_change_short=V365M
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs28399454
|overall_frequency_n=407
|overall_frequency_d=10758
|overall_frequency=0.0378323
|n_genomes=5
|n_genomes_annotated=0
|n_haplomes=5
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|nblosum100=0
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}